3 COLUMBUS CIRCLE, NEW YORK, NY
Indaptus Therapeutics Enters $24 Million Stock Purchase Agreement
Amended material disclosure
Director Resignation - Tim Ruan Steps Down from Indaptus Board
Indaptus Therapeutics Enters Amended At The Market Offering Agreement
Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Indaptus Therapeutics Enters $12M Stock Purchase Agreement
Director Resignations - David E. Lazar and Avraham Ben-Tzvi Step Down
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Amended Registration Statement for Securities
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Amended Schedule 13D - Ownership Report
Initial Statement of Beneficial Ownership
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload
Post-Effective Amendment to Registration Statement